Resverlogix is bringing safe, affordable, first-in-class epigenetic therapeutics to people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Our lead drug candidate, apabetalone, is currently in a Phase 3 clinical trial, BETonMACE, which will be fully enrolled in the first half of 2018.


Resverlogix (TSX:RVX) is a late-stage biotech company with a novel epigenetic approach to reducing the incidence of Major Adverse Cardiac Events (MACE) in high-risk patients. Explore Resverlogix’s advanced clinical platform and discover why now is the time to engage.